Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — Q1 2025 Earnings Presentation
12 slides from Tty Biopharm's earnings presentation, May 27, 2025
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2025.05.27
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Operational Results Report Agenda
Operational Results Report Q1/2025 Operational Highlights Q1/2025 Financial Performance 01 Q1/2025 Operational Highlights 2025 Outlook 2
Slide 4: Strong Revenue Growth in Q1/2025 with Overseas Markets Expansion
1,500 1,274 1,459 2 Strong Revenue Growth in Q1/2025 Consolidated Revenue Consolidated 1,000 1.57 1.5 營運成果報告 412 with Overseas Markets Expansion Operating Profit EPS 500 310 1.13 - 1 Revenue Overview Q1/2024 Q1/2025 Q1/2025 Operational √ Consolidated Revenue √ Consolidated Operating Profit √ EPS Hig
Slide 5: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results 營運成果報告 Q1/2025 Operational Highlights Q1/2025 Financial Performance 2025 Outlook 4
Slide 6: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation 營運成果報告 • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets Q1/2025 Operational Oncology 2025 2026 2027 Hi
Slide 7: Deploy Globally and Expand Overseas Market
Deploy Globally and Expand Overseas Market Operational Results Report • License-in/ collaboration/ sales 130 drugs in 18 countries globally. • The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets. Q1/2025 • Deepen cooperation with
Slide 8: 02 Q1/2025 Financial Performance
Operational Results Report Q1/2025 Operational Highlights 02 Q1/2025 Q1/2025 Financial Performance 2025 Outlook Financial Performance 7
Slide 9: Q1/2025 Financial Performance
Q1/2025 Financial Performance Operational Results Report Income Statement （Unit: NT Thousand, Q1/2025 Q1/2024 YoY % Q1/2025 Financial Performance except EPS） Q1/2025 Net Sales 1,458,850 1,273,605 15% • YoY consolidated revenue was 58.9 billion, +15% due to Operational the high growth of overseas mar
Slide 10: Q1/2025 Steady Revenue Growth
Q1/2025 Steady Revenue Growth Operational Results Report Q1/2025 Revenue Breakdown Q1/2025 Revenue Growth Q1/2025 Operational Highlights Product Category % Revenue (NT Mn) 19% 1,500 14 - 1,459 Q1/2025 Oncology 39% 1,450 31 3% Financial 57 Performance Intensive Care 1,400 83 1,350 Healthcare 20% 2025
Slide 11: 03 2025 Outlook
Operational Results Report Q1/2025 Operational Highlights Q1/2025 Financial Performance 03 2025 Outlook 2025 Outlook 10
Slide 12: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report Strengthen Global Deployment Q1/2025 Operational Highlights 1 Explore potential products and expand international market through authorization, distribution, strategic cooperation and M&A. International Regulations License